Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

AbbVie to acquire Karuna Therapeutics for schizophrenia progress

PUBLIC · ABBVAug 29, 2026•about 4 hours ago

Acquiring Company

AbbVie

Acquired Company

Karuna Therapeutics

BostonBiotechnologyHealth CareTherapeuticsBiopharma

Description

AbbVie has announced its plans to acquire Karuna Therapeutics, valuing the company at multiple billions of dollars. This acquisition emphasizes the strategic importance of Karuna's schizophrenia treatment, KarXT, which has shown promising trial results. The deal reflects the market's confidence in the commercial potential of KarXT. As integration progresses, the focus will shift towards regulatory developments and the future of the combined portfolio.

Company Information

Company

AbbVie

About

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Don't miss AbbVie's next move

Get an email the moment AbbVie makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for AbbVie's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Karuna Therapeutics?

Karuna Therapeutics was acquired by AbbVie. The deal was reported on August 29, 2026. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. AbbVie is publicly traded (ABBV).

When did AbbVie acquire Karuna Therapeutics?

AbbVie's acquisition of Karuna Therapeutics was reported on August 29, 2026. AbbVie has announced its plans to acquire Karuna Therapeutics, valuing the company at multiple billions of dollars. This acquisition emphasizes the strategic importance of Karuna's schizophrenia treatment, KarXT, which has shown promising trial results. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Karuna Therapeutics do?

Karuna Therapeutics, Inc. is a clinical-stage biotherapeutics company with a focus on developing innovative treatment options for patients with psychiatric and neurological conditions. It is privately held, operating in Biotechnology, and is based in Boston.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.